F. Chedevergne

Continuous glucose monitoring to track metabolic changes in youths with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy

Alfonso Galderisi, Hadija Marchiori, Laurence Weiss, Alix Besançon et autres

INTRODUCTION: Glucose tolerance abnormalities can be detected in preschool and school-age children with cystic fibrosis. There is limited data on the impact of CFTR modulator elexacaftor/tezacaftor/ivacaftor (ETI) on their trajectories. We examined CGM metrics before and after ETI initiation across different pediatric …

us, fr, it (code pays fourni par la source)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status in 2 to 5 Year-Old Children Using a Cystic Fibrosis-Specific Multivitamin Formulation

À. Munck, Jeanne Languepin, Raphaël Enaud, F. Chedevergne et autres

Background: Young children with Cystic Fibrosis (CwCF) are at risk of fat-soluble vitamin (FSV) deficiencies due to pancreatic insufficiency, despite pancreatic enzyme supplementation. CFTR modulator therapy such as elexacaftor/tezacaftor/ivacaftor (ETI) may improve pancreatic function, but its impact on FSV levels in this …

fr, us (code pays fourni par la source)

Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis

Anne-Marie Bonnel, T. Roussey-Bihouée, Aurore Blondé, Mélanie Ribault et autres

fr, ca (code pays fourni par la source)

Early Years Matter: Effects of Elexacaftor-Tezacaftor-Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years

Isabelle Sermet‐Gaudelus, Alexia Letierce, Laureline Berteloot, Anne-Marie Bonnel et autres

fr, nl, us, re, be, République centrafricaine (code pays fourni par la source)

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR

Iwona Maria Pranke, Valeria Capurro, B. Chevalier, Emanuela Anna Pesce et autres

Rationale Respiratory status of people with Cystic Fibrosis (pwCF) carrying N1303K is improved by Elexacaftor/Tezacaftor/Ivacaftor (ETI) but, contrary to other mutations, the impact on sweat test results is limited. Methods To explore this discrepancy, we implemented new sweat gland and respiratory cell …

fr, it, us, be, pl (code pays fourni par la source)

Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies

Pierre‐Régis Burgel, Jennifer Da Silva, Emmanuelle Girodon, I. Durieu et autres

fr, it (code pays fourni par la source)

Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children

À. Munck, Raphaël Enaud, Jeanne Languepin, Natascha Remus et autres

Background: Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, …

fr, us (code pays fourni par la source)

P091 Pharmacokinetic of elexacaftor/tezacaftor/ivacaftor in the context of fetal cystic fibrosis therapy

N.H. Truong, S. Benaboud, Paulette Magnas, A.-S. Bonnel et autres

fr (code pays fourni par la source)

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study

Anne-Marie Bonnel, Tiphaine Bihouée, Mélanie Ribault, Marine Driessen et autres

fr (code pays fourni par la source)

Short-term modification of breathprint by Elexacaftor/Tezacaftor/Ivacaftor in a paediatric cohort

Emmanuelle Bardin, Nicolas Hunzinger, Elodie Lamy, Camille Roquencourt et autres

Background The triple combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) translates into major respiratory improvements in adults; yet current clinical endpoints may prove insufficiently sensitive in young children. We hypothesised that ETI rapidly modifies the lungs' metabolism, resulting in changes in breath composition. Methods Eleven children …

fr (code pays fourni par la source)

Elexacaftor-Tezacaftor-Ivacaftor Reduces Bronchial Dilatations in Adolescents with Cystic Fibrosis

Isabelle Sermet‐Gaudelus, Alexia Letierce, Laureline Berteloot, Anne-Marie Bonnel et autres

us, fr, nl, re, be, République centrafricaine (code pays fourni par la source)

623 Impact of a cystic fibrosis–specific multivitamin formulation on fat-soluble vitamin status and treatment satisfaction in preschool-aged children

À. Munck, Raphaël Enaud, Jane Languepin, N. Rémus et autres